• Targets $36 Billion TAM in Early Cancer Detection and MRD.
  • Company in active discussions with global diagnostic leaders to accelerate commercialization.

HENDERSON, Nev., March 18, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, is the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived DNA (ctDNA). Volition announces the submission of an updated manuscript entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy1".

 

The biggest problem facing liquid biopsy worldwide is that the vast majority of circulating DNA in blood plasma samples comes from healthy cells, not cancer cells. In a world first new technology, Volition has overcome this hurdle and produced >99% pure cancer derived plasma DNA sequence sets for liquid biopsy.